JP2906528B2 - Solid preparation for internal use with enhanced absorption - Google Patents
Solid preparation for internal use with enhanced absorptionInfo
- Publication number
- JP2906528B2 JP2906528B2 JP2033491A JP3349190A JP2906528B2 JP 2906528 B2 JP2906528 B2 JP 2906528B2 JP 2033491 A JP2033491 A JP 2033491A JP 3349190 A JP3349190 A JP 3349190A JP 2906528 B2 JP2906528 B2 JP 2906528B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- solid preparation
- internal use
- chlortenoxicam
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Description
【発明の詳細な説明】 ［産業上の利用分野］ 本発明は、速効性を期待するオキシカム系抗炎症剤に
関する。Description: TECHNICAL FIELD The present invention relates to an oxicam anti-inflammatory agent which is expected to have a rapid effect.
［従来の技術］ 従来、オキシカム系抗炎症剤の速効性を検討した技術
は知られていない。[Prior Art] Conventionally, there is no known technique for examining the immediate efficacy of an oxicam anti-inflammatory agent.
［発明が解決しようとする課題］ 従って、オキシカム系抗炎症剤は、鎮痛、歯痛などの
速い吸収を要求される症状には満足できる製剤はなかっ
た。[Problems to be Solved by the Invention] Accordingly, there has been no formulation of an oxicam anti-inflammatory agent that is satisfactory for symptoms requiring fast absorption such as analgesia and toothache.
［課題を解決するための手段］ 本発明者らは、ある種の制酸剤を配合させることによ
り、溶出性が良く、人における吸収の立ち上がりが極め
て速く且つバラツキの少ない製剤を見出し、この知見に
基づき本発明を完成した。[Means for Solving the Problems] The present inventors have found a formulation having a good dissolution property, a very rapid rise in absorption in humans, and a small variation by blending a certain antacid. Based on the above, the present invention has been completed.
本発明は、制酸剤一種または二種以上を配合し、オキ
シカム系抗炎症薬の吸収性を促進することを特徴とする
内服用固形剤である。The present invention is a solid preparation for internal use, which comprises one or more antacids and promotes the absorption of oxicam anti-inflammatory drugs.
本発明で用いられる抗炎症剤とは、クロルテノキシカ
ム、テノキシカム、ピロキシカムなどのオキシカム系抗
炎症薬が挙げられる。The anti-inflammatory agent used in the present invention includes oxicam anti-inflammatory drugs such as chlortenoxicam, tenoxicam, and piroxicam.
本発明で用いられる制酸剤は、炭酸水素ナトリウム、
リン酸水素カルシウム、メタケイ酸アルミン酸マグネシ
ウム、酸化マグネシウム、合成ヒドロタルサイトなどで
ある。The antacid used in the present invention is sodium bicarbonate,
Calcium hydrogen phosphate, magnesium metasilicate aluminate, magnesium oxide, synthetic hydrotalcite, and the like.
本発明で用いられる制酸剤の配合量は、オキシカム系
抗炎症薬の種類、制酸剤の種類や剤形によって異なる
が、オキシカム系抗炎症薬１重量部に対して10重量部〜
50重量部が好ましく、10重量部〜40重量部が更に好まし
い。The amount of the antacid used in the present invention varies depending on the type of the oxicam anti-inflammatory drug, the type and the dosage form of the antacid, but 10 parts by weight to 1 part by weight of the oxicam anti-inflammatory drug.
It is preferably 50 parts by weight, more preferably 10 to 40 parts by weight.
例えば、錠剤の場合は、クロルテノキシカム１重量部
に対して炭酸水素ナトリウムを１重量部以上配合すれば
溶出性が向上し、10重量部以上配合すれば極めて溶出性
が向上する。しかし、20重量部より多く配合すると硬度
が低下し適切な錠剤が得られないし、15重量部より多く
配合するとコーティングの際に割れや欠けができるなど
成形性の面での問題が生じる。For example, in the case of tablets, the dissolution is improved by adding 1 part by weight or more of sodium hydrogencarbonate to 1 part by weight of chlortenoxicam, and the dissolution is extremely improved by adding 10 parts by weight or more. However, if the amount is more than 20 parts by weight, the hardness is lowered and an appropriate tablet cannot be obtained. If the amount is more than 15 parts by weight, problems in formability such as cracking and chipping during coating occur.
この炭酸水素ナトリウム成形性の問題には、リン酸水
素カルシウムなど２種以上の制酸剤を配合することによ
ってある程度解決することができる。The problem of moldability of sodium hydrogen carbonate can be solved to some extent by blending two or more antacids such as calcium hydrogen phosphate.
また合成ヒドロタルサイトであれば、クロルテノキシ
カム１重量部に対して合成ヒドロタルサイト15重量部以
上配合すれば溶出性が向上するが、40重量部より多く配
合するとクロルテノキシカムの吸着が激しくなり、溶出
並びに吸収の低下が認められる。Further, in the case of synthetic hydrotalcite, the dissolution property is improved by blending 15 parts by weight or more of synthetic hydrotalcite with respect to 1 part by weight of chlortenoxicam, but if more than 40 parts by weight, the adsorption of chlortenoxicam becomes severe, Dissolution and reduced absorption are observed.
一方、顆粒剤の場合は、クロルテノキシカム１重量部
に対してメタケイ酸アルミン酸マグネシウム20重量部〜
40重量部を配合すると好ましく、15重量部〜30重量部を
配合すると更に好ましい。40重量部以上になると造粒が
困難となり流動性の良い顆粒が製造できない。また、炭
酸水素ナトリウムの場合はクロルテノキシカム１重量部
に対して炭酸水素ナトリウム１重量部以上であれば溶出
性が向上するが、20重量部以上多く配合すると顆粒の成
形性が悪くなり、コーティングを施す場合には、顆粒表
面が欠けてしまう。On the other hand, in the case of granules, 20 parts by weight of magnesium aluminate metasilicate is used with respect to 1 part by weight of chlortenoxicam.
It is preferable to mix 40 parts by weight, more preferably 15 to 30 parts by weight. If the amount is more than 40 parts by weight, granulation becomes difficult and granules having good fluidity cannot be produced. In the case of sodium bicarbonate, the dissolution property is improved if the amount of sodium bicarbonate is 1 part by weight or more with respect to 1 part by weight of chlortenoxicam. When applied, the granule surface will be chipped.
次に本発明の製剤の製造方法は、錠剤，顆粒とも一般
的な製造方法で製造できる。例えば、オキシカム系抗炎
症薬に制酸剤を加えて、粉砕し、次に賦形剤（例えば、
乳糖、葡萄糖などの糖類、Ｄ−ソルビトール、マンニト
ールなどの糖アルコール類、微結晶セルロースなどのセ
ルロース類、コーンスターチなどの澱粉類、アエロジ
ル）及び崩壊剤（カルボキシメチルセルロースカルシウ
ム、低置換ヒドロキシプロピルセルロースなどのセルロ
ース類、ポリビニルポリピロリドン、クロスカロメロー
スナトリウム）更に、結合剤（ヒドロキシプロピルセル
ロース、ヒドロキシプロピルメチルセルロース、エチル
セルロース、メチルセルロースなどのセルロース類、ポ
リビニルピロリドン）を加えて、混合若しくは粉砕し、
アルコールと精製水の混液で造粒する。造粒は撹拌造粒
機、流動層造粒機、ニーダ、転動造粒機、遠心流動造粒
機、押し出し造粒機、真空造粒機などが使用可能であ
る。次いで、製した造粒物を乾燥し、散剤、細粒剤、顆
粒剤を調製する。Next, in the production method of the preparation of the present invention, both tablets and granules can be produced by a general production method. For example, adding an antacid to an oxicam anti-inflammatory drug, grinding, and then excipients (eg,
Lactose, sugars such as glucose, sugar alcohols such as D-sorbitol and mannitol, celluloses such as microcrystalline cellulose, starches such as corn starch, aerosil) and disintegrants (cellulose such as calcium carboxymethylcellulose and low-substituted hydroxypropylcellulose) , Polyvinylpolypyrrolidone, croscarmellose sodium) and a binder (cellulose such as hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylcellulose, methylcellulose, polyvinylpyrrolidone), and then mixed or pulverized.
Granulate with a mixture of alcohol and purified water. For granulation, a stirring granulator, a fluidized bed granulator, a kneader, a tumbling granulator, a centrifugal fluidized granulator, an extrusion granulator, a vacuum granulator, or the like can be used. Next, the produced granules are dried to prepare powders, fine granules, and granules.
カプセル剤及び錠剤に関しては、造粒物に滑沢剤（例
えば、ステアリン酸マグネシウム、ステアリン酸カルシ
ウム、タルク、硬化油など）を加える。For capsules and tablets, a lubricant (eg, magnesium stearate, calcium stearate, talc, hydrogenated oil, etc.) is added to the granulate.
なお、細粒剤、顆粒剤及び錠剤には、コーティングを
施すことにより、一層服用しやすいものとなる。The fine granules, granules and tablets can be more easily taken by coating.
［発明の効果］ 本発明により、抗炎症薬の速効性が著しく改善され、
鎮痛、歯痛などの速い吸収を要求される症状に有用であ
る。[Effects of the Invention] According to the present invention, the rapid efficacy of an anti-inflammatory drug is significantly improved,
It is useful for symptoms requiring fast absorption such as analgesia and toothache.
［実施例］ 以下、実施例及び試験例を挙げて本発明を具体的に説
明する。EXAMPLES Hereinafter, the present invention will be specifically described with reference to Examples and Test Examples.
実施例１〜８ 表１に示した処方１〜８に基づいてクロルテノキシカ
ムと炭酸水素ナトリウムの配合比を変化させ錠剤を調製
した。Examples 1 to 8 Tablets were prepared by changing the mixing ratio of chlortenoxicam and sodium hydrogen carbonate based on Formulations 1 to 8 shown in Table 1.
調製方法は、次の通りである。即ち、まずクロルテノ
キシカムと炭酸水素ナトリウムを混合粉砕し、次いで乳
糖、微結晶セルロース、アエロジル、低置換ヒドロキシ
プロピルセルロース、及びヒドロキシプロピルセルロー
スを混合した。次に撹拌造粒機（バーチカルグラニュレ
ーター；富士産業社製）にこの混合物を投与し、アルコ
ールと精製水の混液を加え、ブレードの回転を300rpm、
クロススクリューの回転を1000rpmで造粒した。流動層
乾燥機で乾燥後、スピードミルを用い、20メッシュ以下
に整粒した。この整粒した顆粒にステアリン酸マグネシ
ウムを加え、十分に混合した後、打錠機により7mm径の
錠剤を製造した。The preparation method is as follows. That is, chlortenoxicam and sodium bicarbonate were first mixed and pulverized, and then lactose, microcrystalline cellulose, Aerosil, low-substituted hydroxypropylcellulose, and hydroxypropylcellulose were mixed. Next, this mixture was administered to a stirring granulator (vertical granulator; manufactured by Fuji Sangyo Co., Ltd.), a mixture of alcohol and purified water was added, and the blade was rotated at 300 rpm.
The rotation of the cross screw was granulated at 1000 rpm. After drying with a fluid bed dryer, the particles were sized to 20 mesh or less using a speed mill. Magnesium stearate was added to the sized granules, mixed well, and then a tablet having a diameter of 7 mm was produced with a tableting machine.
実施例９ （処方９） クロルテノキシカム 2 mg 炭酸水素ナトリウム 20 mg 燐酸水素カルシウム無水GS 50 mg 微結晶セルロース 40 mg アエロジル 2.5mg 低置換ヒドロキシプロピルセルロース 25 mg ヒドロキシプロピルセルロース 10 mg ステアリン酸カルシウム 0.5mg 合計 150 mg 上記の処方に基づいて実施例１〜８に記載の製造法と
同様にして錠剤を製造した。Example 9 (Prescription 9) Chlortenoxicam 2 mg Sodium bicarbonate 20 mg Calcium hydrogen phosphate anhydrous GS 50 mg Microcrystalline cellulose 40 mg Aerosil 2.5 mg Low-substituted hydroxypropyl cellulose 25 mg Hydroxypropyl cellulose 10 mg Calcium stearate 0.5 mg Total 150 mg Tablets were produced based on the above formulation in the same manner as in the production methods described in Examples 1 to 8.
実施例10,11 表２に示した処方10と処方11に基づいてテノキシカム
及びピロキシカムと炭酸水素ナトリウムの配合比を変化
させ錠剤を調製した。Examples 10, 11 Based on Formulations 10 and 11 shown in Table 2, tablets were prepared by changing the mixing ratio of tenoxicam, piroxicam and sodium hydrogen carbonate.
調製方法は、次の通りである。即ち、まずテノキシカ
ムまたはピロキシカムと炭酸水素ナトリウムを混合粉砕
し、次いで燐酸水素カルシウム無水GS、低置換ヒドロキ
シプロピルセルロース、アエロジル及びヒドロキシプロ
ピルセルロースを混和した。次に撹拌造粒機（バーチカ
ルグラニュレーター；富士産業社製）にこの混合物を投
与し、アルコールと精製水の混液を加え、ブレードの回
転を300rpm、クロススクリューの回転を1000rpmで造粒
した。流動層乾燥機で乾燥後、スピードミルを用い、20
メッシュ以下に整粒した。この整粒した顆粒にステアリ
ン酸マグネシウムを加え、十分に混合した後、打錠機に
より7mm径の錠剤を製造した。The preparation method is as follows. That is, first, tenoxicam or piroxicam and sodium hydrogen carbonate were mixed and pulverized, and then calcium hydrogen phosphate anhydrous GS, low-substituted hydroxypropylcellulose, Aerosil and hydroxypropylcellulose were mixed. Next, this mixture was administered to a stirring granulator (vertical granulator; manufactured by Fuji Sangyo Co., Ltd.), a mixture of alcohol and purified water was added, and the mixture was granulated at a blade rotation of 300 rpm and a cross screw rotation of 1000 rpm. After drying with a fluidized bed dryer, use a speed mill for 20
The granules were sized below the mesh. After magnesium stearate was added to the sized granules and mixed well, tablets having a diameter of 7 mm were produced with a tableting machine.
実施例12 処方９に基づいて一般的な顆粒の製法により製造した
顆粒を３号硬カプセルに充填しカプセル剤を得た。Example 12 Granules produced by a general granule production method based on Formulation 9 were filled into No. 3 hard capsules to obtain capsules.
実施例13 処方10に基づいて一般的な顆粒の製法により製造した
顆粒を３号硬カプセルに充填し、カプセル剤を得た。Example 13 Granules produced by a general granule production method based on Formulation 10 were filled into No. 3 hard capsules to obtain capsules.
実施例14 処方11に基づいて製造した顆粒を３号硬カプセルに充
填し、カプセル剤を得た。Example 14 Granules produced based on Formulation 11 were filled in No. 3 hard capsules to obtain capsules.
試験例１（錠剤の溶出試験） （検体） 検体１〜9;実施例１〜９の錠剤各１個を用いた。Test Example 1 (Dissolution Test of Tablet) (Specimen) Samples 1 to 9; one tablet each of Examples 1 to 9 were used.
対照検体；下記の錠剤各１個。Control sample; one tablet each of the following.
（処方） クロルテノキシカム 2 mg 乳糖 40 mg 微結晶セルロース 41.5mg アエロジル 1 mg 低置換ヒドロキシプロピルセルロース 10 mg ヒドロキシプロピルセルロース 5 mg ステアリン酸マグネシウム 0.5mg 合計 100 mg 上記の処方に基づいて実施例２と同様にして錠剤を製
造した。(Formulation) Chlortenoxicam 2 mg Lactose 40 mg Microcrystalline cellulose 41.5 mg Aerosil 1 mg Low-substituted hydroxypropylcellulose 10 mg Hydroxypropylcellulose 5 mg Magnesium stearate 0.5 mg Total 100 mg Based on the above formulation, the same as in Example 2 To produce tablets.
（試験方法） 人工胃液における溶出試験はバドル法（100rpm）で行
い、人工胃液として日本薬局方・一般試験法崩壊試験の
第Ｉ液（pH＝1.2）900ml（37℃）を用いた。また、溶出
した主薬の定量は吸光度法により行なった。(Test Method) The dissolution test in the artificial gastric juice was performed by the Buddle method (100 rpm), and 900 ml (37 ° C.) of solution I (pH = 1.2) of the Japanese Pharmacopoeia / General Test Method Disintegration Test was used as the artificial gastric juice. The eluted drug was quantified by the absorbance method.
（結果） 表３に示す。(Results) The results are shown in Table 3.
表３に示したように検体6,7は炭酸水素ナトリウムが
全くない処方に比べ、顕著な溶出性の改善が認められ
た。また、炭酸水素ナトリウムのクロルテノキシカムに
対する比率が高くなると主薬の溶出性が良くなっている
が、処方８になると、処方6,7に比べ、初期の溶出が低
くなっていた。これは溶出試験中に錠剤が浮上し、錠剤
の崩壊が延長したためである。また錠剤の浮上は乳糖よ
り比重の軽い、微結晶セルロースを使用したためと思わ
れる。 As shown in Table 3, the releasability of Samples 6 and 7 was significantly improved as compared with the formulation without sodium bicarbonate at all. In addition, the elution of the main drug was improved when the ratio of sodium bicarbonate to chlortenoxicam was increased, but in the case of Formula 8, the initial dissolution was lower than in Formulas 6 and 7. This is because the tablet floated during the dissolution test and the disintegration of the tablet was prolonged. The floating of the tablets is probably due to the use of microcrystalline cellulose, which has a lower specific gravity than lactose.
検体９の人工胃液中における溶出性は、５分で100％
溶出することが認められた。The dissolution of sample 9 in artificial gastric juice is 100% in 5 minutes
Elution was observed.
試験例２（カプセル剤の溶出試験） （検体） 検体1;実施例12のカプセル剤１個。Test Example 2 (Dissolution Test of Capsule) (Specimen) Specimen 1; One capsule of Example 12.
検体2;実施例13のカプセル剤１個。Specimen 2; one capsule of Example 13.
検体3;実施例14のカプセル剤１個。Specimen 3; one capsule of Example 14.
（試験方法） 人工胃液における溶出試験を実施した。尚、溶出試験
はパドル法（100rpm）で行い、人工胃液として日本薬局
方・一般試験法崩壊試験の第Ｉ液（pH＝1.2）900ml（37
℃）を用いた。また、溶出した主薬の定量は吸光度法に
より行なった。(Test method) A dissolution test in artificial gastric juice was performed. The dissolution test was performed by the paddle method (100 rpm), and as an artificial gastric juice, 900 ml of liquid I (pH = 1.2) of the Japanese Pharmacopoeia / General Test Method Disintegration Test (37 mL)
° C) was used. The eluted drug was quantified by the absorbance method.
（結果） 表４に示す。(Results) The results are shown in Table 4.
錠剤と同様の溶出性であった。 The dissolution was similar to that of tablets.
試験例３ （検体） 検体1;実施例９の錠剤１個 対照検体；試験例１で用いた対照検体の錠剤１個 （試験方法） 健康志願者６名による吸収実験をクロスオーバー法に
より実施した。Test Example 3 (Specimen) Specimen 1; 1 tablet of Example 9 Control sample; 1 tablet of the control sample used in Test Example 1 (Test method) An absorption experiment was performed by six healthy volunteers by a crossover method. .
（結果） 結果は，表５に示す。(Results) The results are shown in Table 5.
表５から明らかなように、検体は対照検体に比べtmax
（最高血中濃度到達時間）が早くなり、Cmax（最高血中
濃度）が高くなっている。 As is evident from Table 5, the sample was t max compared to the control sample.
(Time to reach maximum blood concentration) is earlier, and C max (maximum blood concentration) is higher.
試験例４ 実施例6,7,8,9の錠剤各１個を検体１〜４として用い
硬度計（Schleuniger−4M）により、錠剤の硬度を測定
した。Test Example 4 The hardness of the tablets was measured using a hardness meter (Schleuniger-4M) using one tablet of each of Examples 6, 7, 8, and 9 as samples 1 to 4.
（結果） 結果を表６に示す。(Results) The results are shown in Table 6.
錠剤として適切な硬度硬度は、6.0以上の値である。 Hardness suitable for tablets Hardness is a value of 6.0 or more.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 中川 泰緒 東京都豊島区高田３丁目24番１号 大正 製薬株式会社内 (72)発明者 片山 陽子 東京都豊島区高田３丁目24番１号 大正 製薬株式会社内 (58)調査した分野(Int.Cl.6，ＤＢ名) A61K 31/54 A61K 9/16 A61K 9/20 A61K 47/02 A61K 47/24 ＣＡ（ＳＴＮ)──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Yasushi Nakagawa 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. (72) Inventor Yoko Katayama 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. (58) Field surveyed (Int.Cl. 6 , DB name) A61K 31/54 A61K 9/16 A61K 9/20 A61K 47/02 A61K 47/24 CA (STN)
Claims (3)
キシカム系抗炎症薬の吸収性を促進することを特徴とす
る内服用固形剤。(1) A solid preparation for internal use, which comprises one or more antacids to promote absorption of an oxicam anti-inflammatory drug.
カム、テノキシカム、ピロキシカムである請求項１記載
の内服用固形剤。2. The solid preparation for internal use according to claim 1, wherein the oxicam anti-inflammatory drug is chlortenoxicam, tenoxicam, or piroxicam.
素カルシウム、メタケイ酸アルミン酸マグネシウム、酸
化マグネシウム、合成ヒドロタルサイトである請求項１
または請求項２記載の内服用固形剤。3. The antacid is sodium bicarbonate, calcium hydrogen phosphate, magnesium aluminate metasilicate, magnesium oxide, or synthetic hydrotalcite.
Or the solid preparation for internal use according to claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2033491A JP2906528B2 (en) | 1990-02-14 | 1990-02-14 | Solid preparation for internal use with enhanced absorption |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2033491A JP2906528B2 (en) | 1990-02-14 | 1990-02-14 | Solid preparation for internal use with enhanced absorption |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03240729A JPH03240729A (en) | 1991-10-28 |
| JP2906528B2 true JP2906528B2 (en) | 1999-06-21 |
Family
ID=12388029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2033491A Expired - Lifetime JP2906528B2 (en) | 1990-02-14 | 1990-02-14 | Solid preparation for internal use with enhanced absorption |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2906528B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005004915A3 (en) * | 2003-07-09 | 2005-03-17 | Boehringer Ingelheim Int | Compositions comprising meloxicam |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW486370B (en) * | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| WO2000015195A1 (en) * | 1998-09-10 | 2000-03-23 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
| US8231899B2 (en) | 1998-09-10 | 2012-07-31 | Nycomed Danmark Aps | Quick release pharmaceutical compositions of drug substances |
| JP4626202B2 (en) * | 2003-07-16 | 2011-02-02 | 大正製薬株式会社 | Piroxicam-containing external anti-inflammatory analgesic composition |
| CA2565941A1 (en) * | 2004-05-04 | 2005-11-10 | Equitech Corporation | Improved nsaid composition |
| EA200971133A1 (en) * | 2004-06-29 | 2010-10-29 | Никомед Данмарк Апс | MANUFACTURING PHARMACEUTICAL COMPOSITIONS WITH QUICKLY FROZEN ON BASED WATER-SOLUBLE MEDICINES AND PHARMACEUTICAL COMPOSITIONS OBTAINED BY THE METHOD FOR INVENTION |
| EP1817021A1 (en) * | 2004-11-03 | 2007-08-15 | Equitech Corporation | Nsaid compositions exhibiting clinical superiority |
| EP2307022A4 (en) * | 2007-10-31 | 2011-08-24 | Equitech Corp | Enhanced nsaid formulations |
| TWI564008B (en) | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | Formulation for solubility enhancement of poorly soluble drugs |
-
1990
- 1990-02-14 JP JP2033491A patent/JP2906528B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005004915A3 (en) * | 2003-07-09 | 2005-03-17 | Boehringer Ingelheim Int | Compositions comprising meloxicam |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03240729A (en) | 1991-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3967389B2 (en) | Aggregated hydrophilic composite with multiphase release properties | |
| TWI409064B (en) | Pharmaceutical composition | |
| KR940011242B1 (en) | Process for preparing sustained-release pharmaceutical preparations | |
| JP2509226B2 (en) | Nitrofurantoin dosage form | |
| CN101374503B (en) | Quickly disintegrating tablet produced by direct dry-tabletting | |
| TWI325318B (en) | Capsule and method of manufacturing the same | |
| KR20100012867A (en) | Solid dosage forms comprising tadalafil | |
| JPH0733339B2 (en) | Controlled release verapamil tablet | |
| JP2906528B2 (en) | Solid preparation for internal use with enhanced absorption | |
| CN111840239B (en) | Pregabalin sustained release preparation | |
| JP2609022B2 (en) | Polycarbophil calcium-containing preparation | |
| CN1538837A (en) | Swallow tablet comprising paracetamol | |
| JP3884056B1 (en) | Method for producing intraoral rapidly disintegrating tablet | |
| CA2492156C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
| CN103007286B (en) | General smooth solid composite medicament is cut down in a kind of holder | |
| CN114796134A (en) | Calcium polycarbophil tablet easy to rapidly and completely disintegrate | |
| JP4221068B2 (en) | Theophylline sustained release tablet and method for producing the same | |
| CN100490808C (en) | Gliquilone slow-releasing preparation | |
| JP2022130003A (en) | Solid preparation containing chinese medicine extract or vegetable herbal medicine extract, and method for producing the same, and method for improving the ease of disintegration of solid preparation | |
| JPS6087217A (en) | Solid theophilline blend with constant release speed | |
| KR20110007065A (en) | Orally disintegrating tablet and manufacturing method of the same | |
| JP4833464B2 (en) | Method for producing poorly soluble drug-containing solid preparation | |
| JP3967767B1 (en) | Method for producing intraoral rapidly disintegrating tablet | |
| JP2002138055A (en) | Intraoral quick disintegration type compression molding and its production method | |
| JP2001213890A (en) | Trehalose particle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120402 Year of fee payment: 13 |